Fortress Biotech, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Licenses Acquired (Tables)

Licenses Acquired (Tables)

6 Months Ended

Jun. 30, 2020

Schedule of research and development-licenses


	Three Months Ended June 30,				Six Months Ended June 30,
($ in thousands)	2020		2019		2020		2019
Partner companies:
Mustang	$	1,300	$	200	$	1,550	$	650
Oncogenuity		270		—		270		—
Total	$	1,570	$	200	$	1,820	$	650

Schedule of research and development for licenses acquired

For the three and six months ended June 30, 2020 and 2019, Mustang recorded the following expense in research and development for licenses acquired:


	For the Three Months Ended June 30,				For the Six Months Ended June 30,
($in thousands)	2020		2019		2020		2019
City of Hope (COH) - CD123 (MB-102)³	$	334	$	—	$	334	$	250
City of Hope (COH) - IL13Rα2 (MB-101)³		333		—		333		—
City of Hope (COH) - HER2 (MB-103)¹		—		—		250		—
City of Hope (COH) - CS1 (MB-104)		—		200		—		200
City of Hope (COH) - Spacer³		333		—		333		—
Fred Hutch – CD20 (MB-106)²		300		—		300		—
Nationwide Children’s Hospital - C134 (MB-108)		—		—		—		200
Total licenses acquired expense	$	1,300	$	200	$	1,550	$	650

Note 1:

Represents a non-refundable milestone payment in connection with the twentieth patient treated in the Phase 1 clinical study of MB-103 at COH, for the six months ended June 30, 2020.

Note 2:

Represents a non-refundable milestone payment in connection with the twentieth patient treated in the Phase 1 clinical study of MB-106 at Fred Hutch, for the six months ended June 30, 2020.

Note 3:

Represents a milestone payment to COH in connection with Mustang’s public underwritten offerings.